HitGen Forms Second Drug Discovery Partnership with Japan's Kaken

Chengdu's HitGen has signed a licensing agreement to develop a novel class of drugs for Kaken, a Japanese specialty pharma. HitGen has already used its large library of small molecule and macrocyclic compounds to identify potential candidates. Few details were released, but Kaken is known to be concentrating its R&D on inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infections. One year ago, the two companies formed a similar collaboration, presumably for other targets. HitGen will receive an upfront payment and be eligible to receive preclinical and clinical milestones. More details....

Stock Symbol: (TK: 4521)